aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
26 juil. 2018 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference
31 mai 2018 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
17 mai 2018 07h30 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring
14 mai 2018 06h45 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting
02 mai 2018 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
27 nov. 2017 08h00 HE
|
aTyr Pharma, Inc.
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
14 nov. 2017 16h05 HE
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
27 sept. 2017 08h00 HE
|
aTyr Pharma Inc.
SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
aTyr Pharma to Present at Two Upcoming Investor Conferences in September
05 sept. 2017 23h00 HE
|
aTyr Pharma Inc.
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
aTyr Pharma Announces $45 Million Equity Financing
28 août 2017 07h30 HE
|
aTyr Pharma Inc.
SAN DIEGO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the...